To access this element change to forms mode OFF
Grant Award View - GA276582
Developing PKCepsilon-Degrading PROTACs as Dual-Action Agents to Treat...
GA ID:
GA276582
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
27-Oct-2022
Publish Date:
19-Dec-2022
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2025
Value (AUD):
$825,490.65
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Ideas Grants
Grant Activity:
Developing PKCepsilon-Degrading PROTACs as Dual-Action Agents to Treat Type 2 Diabetes
Purpose:
Type 2 diabetes (T2D) is reaching epidemic proportions worldwide, and involves poor insulin production and decreased insulin sensitivity. This collaboration between diabetes researchers and medicinal chemists will translate basic science, demonstrating that inhibiting one enzyme can improve both these defects, into the generation of lead compounds that block this target. We will test inhibitors in models of T2D, providing proof-of-principle for their further development.
GO ID:
GO Title:
Ideas Grants 2022
Internal Reference ID:
2022/GNT2019477
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of New South Wales
Recipient ABN:
57 195 873 179
Grant Recipient Location
Suburb:
Kensington
Town/City:
Kensington
Postcode:
2052
State/Territory:
NSW
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT, NSW, VIC
Postcode:
Multiple
Country:
AUSTRALIA